This consensus paper aims to provide practical, real-world recommendations for the treatment and management of high-risk human epidermal growth factor receptor 2 (HER2)-negative early BC (eBC) carrying BRCA germline pathogenic variant in the Asia-Pacific region. Here, ERBB2 is linked to breast cancer.